Literature DB >> 11903055

Protein kinase A enhances, whereas glycogen synthase kinase-3 beta inhibits, the activity of the exon 2-encoded transactivator domain of heterogeneous nuclear ribonucleoprotein D in a hierarchical fashion.

Mate Tolnay1, Yuang-Taung Juang, George C Tsokos.   

Abstract

Heterogeneous nuclear ribonucleoprotein D (hnRNP D) is implicated in transcriptional regulation. Alternative splicing of exons 2 and 7 generates four isoforms of the protein. We report here that only isoforms that contain the product of exon 2 (amino acids 79-97) were able to transactivate. Moreover, the exon 2-encoded protein domain alone was sufficient to drive transcription. TATA-binding protein and p300 interacted with a synthetic peptide corresponding to exon 2, and both proteins co-precipitated with hnRNP D. Stimulation of protein kinase A (PKA) and protein kinase C (PKC) synergistically induced the transactivating ability of hnRNP D, and the exon 2-encoded domain was sufficient for this inducibility. In kinase assays PKA phosphorylated Ser-87 of hnRNP D, whereas glycogen synthase kinase-3 beta (GSK-3 beta) phosphorylated Ser-83, but only if Ser-87 had been pre-phosphorylated by PKA. Phosphorylation of Ser-87 enhanced, whereas phosphorylation of Ser-83 repressed, transactivation. Overexpression of GSK-3 beta inhibited transactivation by hnRNP D, but stimulation of PKC negated the inhibitory effect of GSK-3 beta. We suggest that a hierarchical phosphorylation pathway regulates the transactivating ability of hnRNP D: PKA activates hnRNP D, but at the same time renders it sensitive to inhibition by GSK-3 beta; the latter inhibition can be suspended by inactivating GSK-3 beta with PKC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11903055      PMCID: PMC1222459          DOI: 10.1042/0264-6021:3630127

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  44 in total

1.  Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity.

Authors:  W J Boyle; T Smeal; L H Defize; P Angel; J R Woodgett; M Karin; T Hunter
Journal:  Cell       Date:  1991-02-08       Impact factor: 41.582

2.  Purification, characterization, and cDNA cloning of an AU-rich element RNA-binding protein, AUF1.

Authors:  W Zhang; B J Wagner; K Ehrenman; A W Schaefer; C T DeMaria; D Crater; K DeHaven; L Long; G Brewer
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

Review 3.  hnRNP proteins and the biogenesis of mRNA.

Authors:  G Dreyfuss; M J Matunis; S Piñol-Roma; C G Burd
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

4.  A minimal transcription activation domain consisting of a specific array of aspartic acid and leucine residues.

Authors:  K Seipel; O Georgiev; W Schaffner
Journal:  Biol Chem Hoppe Seyler       Date:  1994-07

5.  Nuclear proteins that bind the pre-mRNA 3' splice site sequence r(UUAG/G) and the human telomeric DNA sequence d(TTAGGG)n.

Authors:  F Ishikawa; M J Matunis; G Dreyfuss; T R Cech
Journal:  Mol Cell Biol       Date:  1993-07       Impact factor: 4.272

Review 6.  Glycogen synthase kinase-3: functions in oncogenesis and development.

Authors:  S E Plyte; K Hughes; E Nikolakaki; B J Pulverer; J R Woodgett
Journal:  Biochim Biophys Acta       Date:  1992-12-16

7.  Differential regulation of glycogen synthase kinase-3 beta by protein kinase C isotypes.

Authors:  N Goode; K Hughes; J R Woodgett; P J Parker
Journal:  J Biol Chem       Date:  1992-08-25       Impact factor: 5.157

8.  Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling.

Authors:  C Sutherland; I A Leighton; P Cohen
Journal:  Biochem J       Date:  1993-11-15       Impact factor: 3.857

9.  Regulation of in vitro nucleic acid strand annealing activity of heterogeneous nuclear ribonucleoprotein protein A1 by reversible phosphorylation.

Authors:  H Idriss; A Kumar; J R Casas-Finet; H Guo; Z Damuni; S H Wilson
Journal:  Biochemistry       Date:  1994-09-20       Impact factor: 3.162

10.  A secondary phosphorylation of CREB341 at Ser129 is required for the cAMP-mediated control of gene expression. A role for glycogen synthase kinase-3 in the control of gene expression.

Authors:  C J Fiol; J S Williams; C H Chou; Q M Wang; P J Roach; O M Andrisani
Journal:  J Biol Chem       Date:  1994-12-23       Impact factor: 5.157

View more
  6 in total

1.  Thy-1 mRNA destabilization by norepinephrine a 3' UTR cAMP responsive decay element and involves RNA binding proteins.

Authors:  Melissa D LaJevic; Sujatha P Koduvayur; Veronique Caffrey; Rhonna L Cohen; Donald A Chambers
Journal:  Brain Behav Immun       Date:  2010-04-20       Impact factor: 7.217

2.  What Are the bona fide GSK3 Substrates?

Authors:  Calum Sutherland
Journal:  Int J Alzheimers Dis       Date:  2011-05-18

3.  PP2A dephosphorylates Elf-1 and determines the expression of CD3zeta and FcRgamma in human systemic lupus erythematosus T cells.

Authors:  Yuang-Taung Juang; Ying Wang; Guisen Jiang; Hai-Bin Peng; Sukran Ergin; Michelle Finnell; Abigail Magilavy; Vasileios C Kyttaris; George C Tsokos
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

4.  GSK-3: Functional Insights from Cell Biology and Animal Models.

Authors:  Oksana Kaidanovich-Beilin; James Robert Woodgett
Journal:  Front Mol Neurosci       Date:  2011-11-16       Impact factor: 5.639

5.  Arginine methylation enhances the RNA chaperone activity of the West Nile virus host factor AUF1 p45.

Authors:  Susann Friedrich; Tobias Schmidt; Angelika Schierhorn; Hauke Lilie; Grit Szczepankiewicz; Sandra Bergs; Uwe G Liebert; Ralph P Golbik; Sven-Erik Behrens
Journal:  RNA       Date:  2016-08-12       Impact factor: 4.942

6.  Splice-Junction-Based Mapping of Alternative Isoforms in the Human Proteome.

Authors:  Edward Lau; Yu Han; Damon R Williams; Cody T Thomas; Rajani Shrestha; Joseph C Wu; Maggie P Y Lam
Journal:  Cell Rep       Date:  2019-12-10       Impact factor: 9.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.